Cargando…

Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany

OBJECTIVE: To obtain detailed real-world data on persistence and dosing patterns in the utilisation of the TNF inhibitors adalimumab, etanercept, and infliximab in rheumatoid arthritis (RA) patients treated in Germany. METHODS: In this retrospective observational study claims data of a major German...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neubauer, Sarah, Cifaldi, Mary, Mittendorf, Thomas, Ganguli, Arijit, Wolff, Malte, Zeidler, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502064/ https://www.ncbi.nlm.nih.gov/pubmed/26208932 http://dx.doi.org/10.1186/s13561-014-0032-4

Ejemplares similares

Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective
por: Zeidler, Jan, et al.
Publicado: (2012)

Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan
por: Mahlich, Jörg, et al.
Publicado: (2016)

Analysis of Drug and Administrative Costs Allowed by U.S. Private and Public Third-Party Payers for 3 Intravenous Biologic Agents for Rheumatoid Arthritis
por: Stavrakas, Spyros, et al.
Publicado: (2011)

The Effect of TNF and Non-TNF-Targeted Biologics on Body Composition in Rheumatoid Arthritis
por: Vial, Gaelle, et al.
Publicado: (2021)

Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
por: Fragoulakis, Vasilis, et al.
Publicado: (2015)

Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
por: Lim, Heejin, et al.
Publicado: (2018)

Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
por: Schwartzman, Sergio, et al.
Publicado: (2004)

Comparative Persistence of the TNF Antagonists in Rheumatoid Arthritis – A Population-Based Cohort Study
por: Fisher, Anat, et al.
Publicado: (2014)

Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid Arthritis
por: Shafrin, Jason, et al.
Publicado: (2016)

Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?
por: Ramiro, Sofia, et al.
Publicado: (2015)

Damage progression in rheumatoid arthritis: the role of biologic agents
por: Favalli, Ennio Giulio
Publicado: (2012)

Posttraumatic Stress Disorder, Depression, Anxiety, and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis
por: Desilet, Luke W., et al.
Publicado: (2020)

Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?
por: Emery, Paul, et al.
Publicado: (2015)

Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of Methods
por: Krack, Gundula, et al.
Publicado: (2016)

Bone and TNF in rheumatoid arthritis: clinical implications
por: Manara, Maria, et al.
Publicado: (2015)

Pharmacodynamic biomarkers and differential effects of TNF‐ and GM‐CSF‐targeting biologics in rheumatoid arthritis
por: Guo, Xiang, et al.
Publicado: (2018)

Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis
por: Benucci, M, et al.
Publicado: (2012)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis
por: Pallio, Giovanni, et al.
Publicado: (2020)

Biologic Agents in Rheumatoid Arthritis: An Update for Managed Care Professionals
por: Agarwal, Sandeep K.
Publicado: (2011)

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2011)

An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis
por: Vugler, Alexander, et al.
Publicado: (2022)

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
por: Gissel, C., et al.
Publicado: (2016)

TNF-α and TNF-β Gene Polymorphism in Saudi Rheumatoid Arthritis Patients
por: Al-Rayes, Hannan, et al.
Publicado: (2011)

Biological Anti-TNF-α Therapy and Markers of Oxidative and Carbonyl Stress in Patients with Rheumatoid Arthritis
por: Šteňová, Emőke, et al.
Publicado: (2021)

Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis
por: Aaltonen, Kalle J., et al.
Publicado: (2012)

Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis
por: Iwaszko, Milena, et al.
Publicado: (2018)

TCD4(pos) lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFα blocking agents
por: Picchianti Diamanti, Andrea, et al.
Publicado: (2017)

Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis
por: Ursini, Francesco, et al.
Publicado: (2017)

Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
por: Said, Cynthia, et al.
Publicado: (2013)

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
por: Mishra, Richa, et al.
Publicado: (2009)

Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis
por: Kuroda, Takeshi, et al.
Publicado: (2016)

Dopaminergic Agents in Rheumatoid Arthritis
por: Capellino, Silvia
Publicado: (2019)

Modeling rheumatoid arthritis using different techniques - a review of model construction and results
por: Scholz, Stefan, et al.
Publicado: (2014)

Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis
por: Takacs, Peter, et al.
Publicado: (2019)

Optimal dose of etanercept in the treatment of rheumatoid arthritis
por: Curtis, Elizabeth Mary, et al.
Publicado: (2014)

Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study
por: Gilbert, Thomas D, et al.
Publicado: (2004)

Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany
por: Krüger, Klaus, et al.
Publicado: (2020)

Research on Liver Damage Caused by the Treatment of Rheumatoid Arthritis with Novel Biological Agents or Targeted Agents
por: Zhao, Xin, et al.
Publicado: (2023)

Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure
por: Gutierrez-Gonzalez, Luis Arturo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hk6uhaku35um4mc7612f17e4cd